Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gossamer Bio (GOSS) Gains from Investment Securities: 2019-2024

Historic Gains from Investment Securities for Gossamer Bio (GOSS) over the last 6 years, with Dec 2024 value amounting to $5.3 million.

  • Gossamer Bio's Gains from Investment Securities was N/A to $52,000 in Q4 2024 from the same period last year, while for Dec 2024 it was $4.6 million, marking a year-over-year change of. This contributed to the annual value of $5.3 million for FY2024, which is 829.75% up from last year.
  • Gossamer Bio's Gains from Investment Securities amounted to $5.3 million in FY2024, which was up 829.75% from -$726,000 recorded in FY2023.
  • In the past 5 years, Gossamer Bio's Gains from Investment Securities ranged from a high of $5.3 million in FY2024 and a low of -$726,000 during FY2023.
  • Moreover, its 3-year median value for Gains from Investment Securities was $3.0 million (2022), whereas its average is $2.5 million.
  • Its Gains from Investment Securities has fluctuated over the past 5 years, first spiked by 15,245.00% in 2022, then plummeted by 123.97% in 2023.
  • Yearly analysis of 5 years shows Gossamer Bio's Gains from Investment Securities stood at $256,000 in 2020, then tumbled by 107.81% to -$20,000 in 2021, then surged by 15,245.00% to $3.0 million in 2022, then crashed by 123.97% to -$726,000 in 2023, then skyrocketed by 829.75% to $5.3 million in 2024.